Tema Oncology ETF (NASDAQ:CANC) Short Interest Update

Tema Oncology ETF (NASDAQ:CANC) was the recipient of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 1,800 shares, a drop of 18.2% from the March 15th total of 2,200 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily volume of 17,000 shares, the days-to-cover ratio is currently 0.1 days.

Hedge Funds Weigh In On Tema Oncology ETF

A hedge fund recently raised its stake in Tema Oncology ETF stock. Thrivent Financial for Lutherans grew its position in shares of Tema Oncology ETF (NASDAQ:CANC) by 29.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 517,837 shares of the company’s stock after purchasing an additional 118,328 shares during the period. Thrivent Financial for Lutherans owned approximately 20.31% of Tema Oncology ETF worth $13,156,000 as of its most recent SEC filing.

Tema Oncology ETF Trading Down 1.0 %

NASDAQ CANC traded down $0.23 during trading hours on Monday, reaching $22.96. The company had a trading volume of 3,081 shares, compared to its average volume of 11,912. The stock has a market capitalization of $61.76 million, a P/E ratio of 20.79 and a beta of 1.11. The stock has a 50-day moving average of $24.32 and a 200 day moving average of $25.68. Tema Oncology ETF has a 1-year low of $20.10 and a 1-year high of $30.11.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.